EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future

James P Psaltis, Jessica A Marathe, Mau T Nguyen, Richard Le, Christina A Bursill, Chinmay S Marathe, Adam J Nelson, Peter J Psaltis iD

Medicinal Research Reviews · 2025-01 · 45 (1) · 29-65

DOI: 10.1002/med.22070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 14.08.2024. Verfasst von James P Psaltis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Adelaide Medical School, The University of Adelaide, Adelaide, Australia. Hauptthemen laut MEDLINE: Incretins, Cardiovascular Diseases. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Heart Foundation of Australia, Hospital Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among newer classes of drugs for type 2 diabetes mellitus (T2DM), glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) are incretin‐based agents that lower both blood sugar levels and promote weight loss. They do so by activating pancreatic GLP‐1 receptors (GLP‐1R) to promote glucose‐dependent insulin release and inhibit glucagon secretion. They also act on receptors in the brain and gastrointestinal tract to suppress appetite, slow gastric emptying, and delay glucose absorption. Phase 3 clinical trials have shown that GLP‐1 RAs improve cardiovascular outcomes in the setting of T2DM or overweight/obesity in people who have, or are at high risk of having atherosclerotic cardiovascular disease. This is largely driven by reductions in ischemic events, although emerging evidence also supports benefits in other cardiovascular conditions, such as heart failure with preserved ejection fraction. The success of GLP‐1 RAs has also seen the evolution of other incretin therapies. Tirzepatide has emerged as a dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 RA, with more striking effects on glycemic control and weight reduction than those achieved by isolated GLP‐1R agonism alone. This consists of lowering glycated hemoglobin levels by more than 2% and weight loss exceeding 15% from baseline. Here, we review the pharmacological properties of GLP‐1 RAs and tirzepatide and discuss their clinical effectiveness for T2DM and overweight/obesity, including their ability to reduce adverse cardiovascular outcomes. We also delve into the mechanistic basis for these cardioprotective effects and consider the next steps in implementing existing and future incretin‐based therapies for the broader management of cardiometabolic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsCardiovascular DiseasesHumansDiabetes Mellitus, Type 2AnimalsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

atherosclerosisdiabetesincretinsobesitytirzepatide

Substanzen

IncretinsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Adelaide Medical School, The University of Adelaide, Adelaide, Australia.
  • Heart and Vascular Health Program, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.
  • Department of Cardiology, Central Adelaide Local Health Network, Adelaide, Australia.
  • College of Medicine and Public Health, Flinders University, Adelaide, Australia.
  • Department of Endocrinology, Central Adelaide Local Health Network, Adelaide, Australia.

ORCID-Profile: Peter J Psaltis

Förderung

  • National Heart Foundation of Australia
  • Hospital Research Foundation

Zitieren

APA

Psaltis, J. P., Marathe, J. A., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2025). Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future. Medicinal Research Reviews, 45(1), 29-65. https://doi.org/10.1002/med.22070

Vancouver

Psaltis JP, Marathe JA, Nguyen MT, Le R, Bursill CA, Marathe CS, et al. Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future. Medicinal Research Reviews. 2025;45(1):29-65. doi:10.1002/med.22070

BibTeX
@article{Psaltis2025,
  author = {Psaltis, James P and Marathe, Jessica A and Nguyen, Mau T and Le, Richard and Bursill, Christina A and Marathe, Chinmay S and Nelson, Adam J and Psaltis, Peter J},
  title = {Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future},
  journal = {Medicinal Research Reviews},
  year = {2025},
  volume = {45},
  number = {1},
  pages = {29--65},
  doi = {10.1002/med.22070}
}
Kostenlos starten →